Literature DB >> 32711803

The link between kidney disease and cancer: complications and treatment.

Jolanta Malyszko1, Petra Tesarova2, Giovambattista Capasso3, Anna Capasso4.   

Abstract

Acute and chronic kidney disease encompasses a complex set of diseases that can both lead to, and result from, cancer. In particular, kidney disease can arise from the use of chemotherapeutic agents. Many of the current and newly developed cancer chemotherapeutic agents are nephrotoxic and can promote kidney dysfunction, which frequently manifests during the terminal stages of cancer. Given the link between kidney disease and cancer development and treatment, the aim of this Review is to highlight the importance of multidisciplinary collaboration between oncologists and nephrologists to predict and prevent chemotherapeutic-induced nephrotoxicity. As new therapies are introduced to treat cancer, new renal toxicities require proper diagnosis and management. We anticipate that multidisciplinary collaborations will lead to the development and implementation of guidelines for clinicians to improve the therapeutic management of patients with both cancer and renal impairment.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32711803     DOI: 10.1016/S0140-6736(20)30540-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  Leveraging electronic health record data for clinical trial planning by assessing eligibility criteria's impact on patient count and safety.

Authors:  James R Rogers; Jovana Pavisic; Casey N Ta; Cong Liu; Ali Soroush; Ying Kuen Cheung; George Hripcsak; Chunhua Weng
Journal:  J Biomed Inform       Date:  2022-02-18       Impact factor: 6.317

2.  Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.

Authors:  Yuntao Bai; Ji Young Kim; Bijay Bisunke; Laura A Jayne; Josie A Silvaroli; Michael S Balzer; Megha Gandhi; Kevin M Huang; Veronika Sander; Jason Prosek; Rachel E Cianciolo; Sharyn D Baker; Alex Sparreboom; Kenar D Jhaveri; Katalin Susztak; Amandeep Bajwa; Navjot Singh Pabla
Journal:  Kidney Int       Date:  2021-09-15       Impact factor: 18.998

3.  Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study.

Authors:  Zhiyao Bao; Lifeng Luo; Tian Xu; Jin Yang; Mengchen Lv; Lei Ni; Xianwen Sun; Wei Chen; Lin Zhou; Xiaofei Wang; Yi Xiang; Beili Gao
Journal:  Ann Transl Med       Date:  2022-09

4.  Association between chronic kidney disease and cancer including the mortality of cancer patients: national health and nutrition examination survey 1999-2014.

Authors:  Kanglin Guo; Zufeng Wang; Ran Luo; Yichun Cheng; Shuwang Ge; Gang Xu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

Review 5.  Iron imbalance in cancer: Intersection of deficiency and overload.

Authors:  Tulika Basak; Rupinder Kaur Kanwar
Journal:  Cancer Med       Date:  2022-04-22       Impact factor: 4.711

Review 6.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.

Authors:  Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

7.  Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.

Authors:  Marije S Koks; Gurbey Ocak; Britt B M Suelmann; Cornelia A R Hulsbergen-Veelken; Saskia Haitjema; Marieke E Vianen; Marianne C Verhaar; Karin A H Kaasjager; Meriem Khairoun
Journal:  PLoS One       Date:  2021-06-08       Impact factor: 3.240

8.  Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer.

Authors:  Bogdana Schmidt; Kyla N Velaer; I-Chun Thomas; Calyani Ganesan; Shen Song; Alan C Pao; Alan E Thong; Joseph C Liao; Glenn M Chertow; Eila C Skinner; John T Leppert
Journal:  Eur Urol Open Sci       Date:  2022-01-03

9.  Incidence of death from kidney diseases among cancer patients: a US population-based analysis.

Authors:  Xiaoli Li; Wenhui Chen; Jinfang Feng; Bo Zhao
Journal:  Int Urol Nephrol       Date:  2021-03-08       Impact factor: 2.370

Review 10.  Challenging patient phenotypes in the management of anaemia of chronic kidney disease.

Authors:  Sheena Pramod; David S Goldfarb
Journal:  Int J Clin Pract       Date:  2021-08-12       Impact factor: 3.149

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.